Movement Alert｜BIOCYTOGEN-B falls 6.31% in Regular Trading, recent institutional stake increases fail to prevent continued share-price pressure

Market Focus11-03 13:23

On November 3, BIOCYTOGEN-B fell 6.31% in Regular Trading, trading at HK$36.72, with turnover of HK$28.37 million.

The most recent company-specific development was a disclosed on-market purchase by FMR LLC, which bought 100,500 shares on October 28 at an average price of HK$42.3527 per share for about HK$4.26 million, lifting its long position from 4.95% to 5.04%. Earlier, E Fund Management also bought 86,000 shares on October 27 at an average price of HK$41.0028, raising its long position to 6.01%.

Separately, BIOCYTOGEN-B reported strong first-nine-month results on October 29, with revenue of RMB1.403 billion rising 49.09% year on year and net profit attributable to shareholders of RMB312 million rising 173.77%. Despite these updates, the stock is now trading below the disclosed institutional purchase prices, indicating that near-term selling pressure has remained in place.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment